Skip to main content
Signal8

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

$NWBOPress releaseJul 8, 2026, 2:43 PM ET

Independent analyses of the Phase III DCVax-L trial for glioblastoma reveal that the treatment's survival extension was likely underestimated in the original cohort-based review. Using individual patient data, statisticians found a median survival advantage of 4.9 to 6.3 months, significantly higher than the 2.8 months previously reported. The updated Hazard Ratios ranged from 0.69 to 0.77 with p-values between 0.004 and 0.027, indicating a statistically significant reduction in the risk of death. Sensitivity analyses confirmed that these results were not driven by hidden imbalances between the DCVax-L patients and control groups.

Key figures

Drug Name
DCVax-L
Phase Of Trial
Phase III
P value range
0.004-0.027
Patient count
331
Hazard ratio range
0.69-0.77
Survival advantage months psm low
4.9
Survival advantage months original
2.8
Survival advantage months psm high
6.3

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.